Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Tuesday.
A number of other equities research analysts have also issued reports on ADAP. Leerink Swann reaffirmed an “outperform” rating on shares of Adaptimmune Therapeutics in a research note on Thursday, March 15th. ValuEngine raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Finally, Zacks Investment Research lowered Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, March 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $11.58.
ADAP opened at $12.36 on Tuesday. The company has a market capitalization of $1,166.44, a P/E ratio of -15.45 and a beta of 1.16. Adaptimmune Therapeutics has a 1-year low of $4.28 and a 1-year high of $13.41.
Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). The firm had revenue of $4.27 million during the quarter, compared to analyst estimates of $9.38 million. Adaptimmune Therapeutics had a negative return on equity of 32.26% and a negative net margin of 185.39%. analysts expect that Adaptimmune Therapeutics will post -0.82 earnings per share for the current year.
In related news, major shareholder Enterprise Associates 14 New bought 6,571,164 shares of Adaptimmune Therapeutics stock in a transaction that occurred on Tuesday, March 27th. The shares were purchased at an average price of $1.92 per share, with a total value of $12,616,634.88. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Orbimed Advisors Llc sold 1,048,067 shares of the company’s stock in a transaction that occurred on Thursday, March 29th. The shares were sold at an average price of $11.50, for a total value of $12,052,770.50. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 9,385,254 shares of company stock worth $17,966,655. 24.45% of the stock is owned by corporate insiders.
Hedge funds have recently bought and sold shares of the stock. Raymond James & Associates purchased a new stake in Adaptimmune Therapeutics in the 4th quarter valued at approximately $114,000. Cubist Systematic Strategies LLC purchased a new stake in Adaptimmune Therapeutics in the 3rd quarter valued at approximately $182,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Adaptimmune Therapeutics during the 4th quarter worth $244,000. California Public Employees Retirement System purchased a new position in shares of Adaptimmune Therapeutics during the 4th quarter worth $287,000. Finally, OxFORD Asset Management LLP lifted its stake in shares of Adaptimmune Therapeutics by 30.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 45,238 shares of the biotechnology company’s stock worth $369,000 after purchasing an additional 10,471 shares during the period. 55.50% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This piece was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/04/17/adaptimmune-therapeutics-adap-rating-increased-to-buy-at-bidaskclub.html.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.